By
The company, which said last month it was viewing all strategic options, has entered into discussions with Italy's Gruppo Angelini, its U.S. partner, after a review of its effort to commercialize antidepressant Oleptro in the United States.
In March, Labopharm replaced its chief executive officer and cut its workforce.